Nous-209 has been developed using the Nouscom's viral vector platform, which includes adenoviral and Modified Vaccinia Ankara (MVA) vectors, with MVA vectors manufactured using ProBioGen's AGE1.CR.pIX. This is Nouscom's third and most advanced clinical candidate benefitting from ProBioGen's production cell platform. The milestone represents a significant step towards bringing new, innovative products to patients and further underscores ProBioGen's commitment to supporting the development of life-changing treatments. Significant undisclosed milestone payments have been received by ProBioGen.

Dr. Richard Davis, Chief Operating Officer at Nouscom said: "Based on compelling early clinical and translational data, we are delighted with the progression of NOUS-209 into randomized global phase 2 clinical trials. ProBioGen's AGE1.CR.pIX cell line has allowed us to develop a reproduceable and scalable process for MVA manufacture, and we look forward to furthering our close relationship as we continue to progress our pipeline through clinical trials."

"We commend Nouscom for achieving this important milestone with this prime-boost vaccine approach addressing a clear unmet need", stated ProBioGen's Chief Scientific Officer, Dr. Volker Sandig. "In this case it is also a testament to our AGE1.CR.pIX production technology as a most advanced solution to manufacture a potent viral vector.